March 16, 2018 10:30 AM EDTUpdated 01:58 PM
Peer Review

Long­time R&D chief Bischof­berg­er leaves Gilead; No­var­tis op­er­a­tions chief heads out; Astel­las taps Bar­ret­to-Ko to run Amer­i­c­as op­er­a­tions

Amber Tong

→ Af­ter a stretch of close to 30 years at Gilead $GILD, long­time R&D chief Nor­bert Bischof­berg­er is leav­ing the com­pa­ny. He’ll be step­ping out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times